



PRESS RELEASE

Inside Therapeutics raises €1.3M to accelerate patient access to RNA therapies

Angoulême, France, June 20, 2024.

Inside Therapeutics, a company that designs, develops and markets systems for **encapsulating RNA for therapeutic purposes in lipid nanoparticles**, has raised €1.3 million from Newfund Heka, Newfund NAEH, Skalepark and business angels. The first round of financing was carried out with the support of the ADI NA (Agence de Développement et d'Innovation de Nouvelle-Aquitaine) fund-raising department.

Lipid nanoparticles (LNPs) protect and deliver molecules of interest to target cells. These advanced nanovectors can also help cross certain physiological barriers and specifically target certain organs, such as the brain. Their use for **delivering RNA therapeutic** emerged in the 2010s and was brought to the spotlight by the success of Moderna and Pfizer-BioNTech's COVID-19 vaccines. This method offers significant advantages: **precise cell targeting, enhanced therapeutic effects, and reduced adverse effects**. However, current nanoparticle manufacturing technologies fall short of covering all stages of nanomedicine development, from early, low-volume preclinical phases to large-scale, **GMP-compliant production**. This limitation significantly hinders the development and commercialization of these innovative therapies.

Inside Therapeutics has developed a proprietary technology for encapsulating RNA in lipid nanoparticles, making RNA encapsulation more efficient and covering all stages of drug development with a single method. This ensures consistent production of identical nanoparticles throughout the process and therefore **saves time and reduces the risk of failure for industry stakeholders**.



"Our first TAMARA nanoparticle formulation system meets the R&D challenges of public and private laboratories working on the development of «mRNA candidate» therapies. Our NANOPULSE technology enables nanomedicine manufacturing to be scaled up, from the early stages of drug candidate development through to clinical trials and large-scale manufacturing of RNA therapies"

Thomas Guérinier, co-founder and CEO of Inside Therapeutics

With **more than thirty customers worldwide**, this round of funding will help us further position our solutions in universities, biotech and pharmaceutical companies, particularly in the USA, helping to accelerate the development of their candidate RNA therapies. The company plans to recruit approximately ten employees over the next 18 months.

Inside Therapeutics already has **the support of key players in France's biomanufacturing ecosystem**:

"We are delighted to welcome Inside Tx as a member of France BioLead, and to see how attractive the biomanufacturing of mRNA therapies is to investment funds"

emphasizes Laurent Lafferrère, CEO of France BioLead




The **next step** for Inside Therapeutics is to industrialize its proprietary NanoPulse technology for encapsulating RNA in lipid nanoparticles. This technology should accelerate the development of the **several hundred RNA therapies** currently being worked on by numerous biotech and pharmaceutical companies. This will facilitate access to revolutionary RNA therapies for patients suffering from infectious diseases, cancers or rare diseases.

"We are proud to have a diverse and robust panel of investors supporting us: Newfund's strength, its roots in the Nouvelle Aquitaine region through the Newfund Naeh fund, and its national and US visibility with Newfund Heka, are great assets for the success of our project. We are also backed by Skalepark, business angels, and our long-standing investor, Microfluidic Innovation Center, as part of this strategic financing round"

says Thomas Guerinier

"The maturity of the Inside Tx project, as well as that of the founders, is impressive! In a short space of time, the team has transformed a research project into a high value-added product, marketed worldwide. The solutions offered by Inside Tx meet the new challenges of the pharmaceutical industry and are part of a fast-growing market! We are therefore very proud to have completed our 17th investment, and to be able to support them in the challenges ahead!"

says SkalePark's Yvan Cantou





About Inside Therapeutics

Founded in July 2022, Inside Therapeutics designs, develops and markets instruments for **encapsulating therapeutic molecules** such as RNA in lipid nanoparticles. Once synthesized, these nanoparticles are injected into humans, carrying the molecule to the target cells. In addition to RNA vaccines against infectious diseases such as Covid, applications for this technology include cancers and rare genetic diseases. Inside Tx's aim is to accelerate patient access to RNA therapies, a true revolution in healthcare.

insidetx.com – contact@insidetx.com



About Newfund

Newfund is the only 100% early-stage VC with a dual presence in France and the United States. Since its launch in 2008, Newfund has invested in over 150 start-ups, nearly a third of which are American.

Through its HealthTech Newfund HEKA fund, launched in 2023, Newfund aims to finance 25 technology start-ups linked to brain health and its competencies. The fund participates in seed and Series A financing rounds, with initial tickets ranging from €500k to €2m, to support initial international development, and provides long-term support for follow-on entrepreneurs.

With the launch of its second Newfund NAEH2 fund in 2023, Newfund is continuing to invest in New Aquitaine, with the aim of financing around twenty start-ups in the region. The fund participates in pre-seed and seed financing rounds, with initial tickets ranging from €250k to €1M, and provides long-term support for founders.

On the subscriber side, Newfund brings together the broadest base of entrepreneurs and family offices in France for an innovation fund.

<https://newfundcap.com>



About SkalePark

SkalePark is a family office founded in 2020 by Jean François Clédél and Yvan Cantou, both engineers and entrepreneurs from Gironde. SkalePark invests in ambitious tech & deeptech projects led by committed teams. We are convinced that, over and above our financial contribution, our experience and involvement alongside the founders will be decisive in the project's success.

<https://www.skalepark.com>

About Marc Le Bozec

Marc Le Bozec has been an entrepreneur and investor in the life sciences sector for over 25 years. He has held executive positions (Chairman of the Board, Director, CEO and CFO) in a number of companies, including BioProtein Technologies, Collectis, Cytoo and more recently Neurodyx. He has created and managed two investment funds within Financière Arbevel: an OPCVM dedicated to innovative listed European healthcare companies, and an FPCI with a capital of forty million euros, thanks to which Marc has made 11 investments, including 10 in France. Marc is a graduate of HEC (1992).



About ADI Nouvelle-Aquitaine

ADI Nouvelle-Aquitaine was born out of a desire to make the regional economy more competitive and has placed innovation at the core of its mission of supporting and creating opportunities. ADI Nouvelle-Aquitaine values the virtues of teamwork and mobilizes in-house innovation skills or identifies opportunities within the ecosystem.

ADI N-A's «Fundraising» service helps start-ups to raise private funds from French private equity players. Since its creation in 2010, more than 100 private fundraising rounds have been completed for a total of over €90 million. This support is based on the www.fundmeup.fr platform, which brings together entrepreneurs in the Nouvelle-Aquitaine region who are in the process of raising funds, and investors from all horizons who wish to contact companies that are opening their capital.

www.fundmeup.fr - www.adi-na.fr

Contact :

Pierre LAINE, Chargé de mission Levée de fonds
0626067813 – p.laine@adi-na.fr



Carrying **care** with **precision**

Inside Therapeutics

Cité Numérique, Batiment B5
2 rue Marc Sagnier
33130 Bègles, France

insidetx.com

contact@insidetx.com

